NEOsphere Biotechnologies GmbH

NEOsphere Biotechnologies is a privately funded, Munich-based biotech start-up. Founded by world leading experts in proteomics-based drug discovery, we use the latest mass spectrometry technology to screen entire compound libraries against proteomes of more than 10,000 proteins. Our focus is on targeted protein degradation, and we partner with pharmaceutical and biotech companies to link innovative degrader chemistries to the previously undruggable proteome.